Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000 boxes of the gastresophageal reflux disease (GERD) medication Pariet (rabeprazole) to the Beijing Health Alliance Charitable Foundation. This initiative is designed to support a new program aimed at enhancing the capabilities of grassroots health care facilities across China, with additional sponsorship from the Jiren Charity Foundation.
As a therapeutic medication for digestive system diseases, rabeprazole will be beneficial for patients suffering from chronic gastritis, gastric ulcers, and other related conditions. In the 9th volume-based procurement (VBP) round in China, rabeprazole saw eight domestic manufacturers secure contracts for its generic versions, excluding the originator drug from Eisai. This procurement event resulted in public hospitals agreeing to purchase a total of 130 million tablets of rabeprazole, valued at RMB 36 million.- Flcube.com
